Li Z, Chen Z W, Ren H, Hu P
Department of Infectious Diseases, Institute for Viral Hepatitis, the Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
Zhonghua Gan Zang Bing Za Zhi. 2017 Mar 20;25(3):170-174. doi: 10.3760/cma.j.issn.1007-3418.2017.03.003.
Direct-acting antiviral agents (DAAs) achieve a high sustained virologic response rate in the treatment of chronic hepatitis C virus infection. However, drug resistance-associated mutations play an important role in treatment failure and have attracted more and more attention. This article elaborates on the clinical significance of drug resistance-associated mutations from the aspects of their definition, association with genotype, known drug resistance-associated mutations and their prevalence rates, the impact of drug resistance-associated mutations on treatment naive and treatment-experienced patients, and the role of clinical detection, in order to provide a reference for clinical regimens with DAAs and help to achieve higher sustained virologic response rates.
直接作用抗病毒药物（DAAs）在慢性丙型肝炎病毒感染的治疗中可实现较高的持续病毒学应答率。然而，耐药相关突变在治疗失败中起重要作用，并且已引起越来越多的关注。本文从耐药相关突变的定义、与基因型的关联、已知的耐药相关突变及其流行率、耐药相关突变对初治和经治患者的影响以及临床检测的作用等方面阐述其临床意义，以便为使用DAAs的临床方案提供参考，并有助于实现更高的持续病毒学应答率。
